Ipsen Wrexham investment unveiled as Wrexham mayor joins 50th birthday celebration
Ipsen today announced a £75 million investment in its Wrexham site, a world-renowned “neuroscience centre of excellence.” The announcement coincides with the site’s 50th birthday, which was celebrated with a tree-planting ceremony attended by the newly appointed Wrexham Mayor, members of the community, and Ipsen employees, including the company’s Chief Executive Officer, David Loew.
The event commemorated half a century of researching, developing and manufacturing innovative treatments for patients in over 90 countries across the world, with the tree-planting ceremony serving as a symbol of the company’s strong roots in North Wales, sustainable work practices, commitment to the environment, and future growth.
Wrexham’s new Mayor, Councillor Andy Williams, who took part in the tree-planting ceremony, said, “Today marks a significant milestone for Ipsen as a company, and for the Wrexham community. Through the creation of numerous jobs over five decades, Ipsen’s Wrexham site has contributed significantly to the growth of the local economy while working sustainably and ethically, making it a shining example to businesses locally and globally. From driving global health to ‘going green’ and helping local students pursue careers in the life sciences sector, Ipsen Wrexham has much to be proud of as a community partner and global innovator.”
Ipsen Wrexham, which is the largest of Ipsen’s UK sites, uses 100% renewable energy across its production and research units. Earlier in the year, the Wrexham-based global manufacturing site was awarded a grant by the government in recognition of its outstanding contributions to the life sciences ecosystem.
“The 50th anniversary of Ipsen’s Wrexham site marks a proud moment for our company,” said David Loew. “We have seen huge growth in demand at this important site, and we are pleased to continue our investment in the area and contribute positively to the local economy.”
Ipsen Wrexham is a global site, producing products that are exported to more than 90 countries around the world. It currently houses approximately 500 Ipsen employees, including scientists focused on developing a range of scientifically advanced, high-quality processes and methodologies required for the manufacture and supply of clinical products across the Ipsen Biologics portfolio. It was recently named as one of the UK’s Best Workplaces™ (2023) in the category of large organisations, by Great Place to Work®, the global authority on workplace culture.